Creative Medical Secures Second WHO Proposed INN 'etaroleucel' for CELZ-101
Creative Medical achieved its second WHO International Nonproprietary Name milestone with the proposed INN 'etaroleucel' for autologous Treg therapy CELZ-101, now entering the formal objection period. This builds on the 'olastrocel' naming for allogeneic CELZ-201 and enhances global regulatory positioning for its cell therapy programs.
1. Second WHO INN Milestone Achieved
Creative Medical obtained its second International Nonproprietary Name milestone with the WHO for the proposed INN 'etaroleucel' corresponding to its autologous regulatory T-cell (Treg) immunotherapy program CELZ-101. The name was published in Proposed INN List 134 following the 80th WHO INN Consultation and is now in the formal objection period prior to final approval.
2. Building on Prior INN Recognition
This milestone follows the prior WHO assignment of 'olastrocel' for its lead allogeneic cell therapy program CELZ-201, published in Proposed INN List 133 after the 79th INN Consultation. The dual INN achievements underscore Creative Medical’s ability to advance multiple distinct cell therapy platforms through established global naming processes.
3. Implications for Clinical and Commercial Strategy
INN assignments facilitate standardized substance identification, aiding global clinical trial design, regulatory submissions, and eventual product labeling. Recognition of both etaroleucel and olastrocel positions Creative Medical to streamline international development pathways and supports long-term commercial planning for therapies targeting Type 1 diabetes, chronic lower back pain, cardiovascular and hepatic applications.